Clonality genetic divergence in multifocal superficial urothelial carcinoma as determined by chromosome 9 and p53 deletion analysis

Laboratory Investigation

Volumn 80, Issue 5, 2000, Pages 709-718

  Hartmann, Arndt ^a   Rösner, Ursula ^a   Schlake, Gudrun ^a   Dietmaier, Wolfgang ^a   Zaak, Dirk ^b   Hofstaedter, Ferdinand ^a   Knuechel, Ruth ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADULT; AGED; ALLELE; ARTICLE; BLADDER CARCINOMA; CHROMOSOME 17; CHROMOSOME 9P; CHROMOSOME ANALYSIS; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE LOCUS; GENE MUTATION; GENETIC HETEROGENEITY; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MALE; MOLECULAR CLONING; PRIORITY JOURNAL;

EID: 0343618659     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1038/labinvest.3780074     Document Type: Article

References (43)

1. Baud E, Catilina P, Boiteux J-P, and Bignon Y-J (1998). Human bladder cancers and normal bladder mucosa present the same hot spot of heterozygous chromosome-9 deletion, Int J Cancer 77:821-824.
2. Bender CM, and Jones PA (1998). Molecular genetics in carcinoma of the bladder. In: Petrovich Z, Baert L, and Brady LW, editors. Carcinoma of the bladder: Innovations in management. Heidelberg, New York: Springer, pp. 37-51.
3. Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, Mao L, Herath J, Jenkins R, Westra W, Rutter JL, Buckler A, Gabrielson E, Tockman M, Cho KR, Hedrick L, Bova GS, Isaacs W, Gocj W, Schwab D, and Sidransky D (1995). Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nature Genet 11:210-212.
4. Canzian F, Salovaara R, Hemminki A, Kristo P, Chadwick RB, Aaltonen LA, and de la Chapelle A (1996). Semiautomated assessment of loss of heterozygosity and replication error in tumors. Cancer Res 56:3331-3337.
5. Chaturverdi V, Li L, Hodges S, Johnston D, Ro JY, Logothetis C, von Eschenbach AC, Batsakis JG, and Czerniak B (1997). Superimposed histologic and genetic mapping of chromosome 17 alterations in human urinary bladder neoplasia. Oncogene 14:2059-2070.
6. Dietmaier W, Hartmann A, Wallinger S, Heinmöller E, Kerner T, Endl E, Jauch KW, Hofstädter F, and Rüschoff J (1999). Multiple mutation analyses in single tumor cells with improved whole genome amplification. Am J Pathol 154:83-95.
7. Fearon ER, and Vogelstein B (1990). A genetic model for colorectal tumorigenesis. Cell 61:759-763.
8. Futreal PA, Barrett JC, and Wiseman RW (1991). An Alu polymorphism intragenic to the p53 gene. Nucl Acids Res 19:6977.
9. Goto K, Konomoto T, Hayashi K, Kinukawa N, Naito S, Kumuzawa J, and Tsuneyoshi M (1997). p53 mutations in multiple urothelial carcinomas: A molecular analysis of the development of multiple carcinomas. Mod Pathol 10:428-437.
10. Habuchi T, Takahashi R, Yamada H, Kakehi Y, Sugiyama T, and Yoshida O (1993). Metachronous multifocal development of urothelial cancers by intraluminal seeding. Lancet 342:1087-1088.
11. Habuchi T, Yoshida O, and Knowles MA (1997). A novel candidate tumour suppressor locus at 9q32-33 in bladder cancer: Localization of the candidate region within a single 840 kb YAC. Hum Mol Gen 6:913-919.
12. Habuchi T, Luscombe M, Elder PA, and Knowles MA (1998). Structure and methylation-based silencing of a gene (DB-CCR1) within a candidate bladder cancer tumor suppressor region at 9q32-q33. Genomics 48:277-288.
13. Harris AL, and Neal DE (1992). Bladder cancer-field versus clonal origin. N Engl J Med 326:759-761.
14. Hartmann A, Moser K, Kriegmair M, Hofstetter A, Hofstaedter F, and Knuechel R (1999). Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma. Am J Pathol 154:721-727.
15. Heney NM, Daly J, Prout GR Jr, Nieh PT, Heaney JA, and Trebeck NE (1978). Biopsy of apparently normal urothelium in patients with bladder carcinoma. J Urol 120:559-560.
16. Hruban RH, Van der Riet P, Erozan YS, and Sidransky D (1994). Brief report: Molecular biology and the early detection of carcinoma of the bladder: The case of Hubert H. Humphrey. N Engl J Med 330:1276-1278.
17. Keen AJ, and Knowles MA (1994). Definition of two regions of deletion on chromosome 9 in carcinoma of the bladder. Oncogene 9:2083-2088.
18. Kriegmair M, Baumgartner R, Knuchel R, Stepp H, Hofstadter F, and Hofstetter A (1996). Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence [see comments]. J Urol 155:105-109.
19. Lee S, and Rasheed S (1990). A simple procedure for maximum yield of high-quality plasmid DNA. Biotechniques 9:676-679.
20. Linnenbach AJ, Pressler LB, Seng BA, Kimmel BS, Tomaszewski JE, and Malkowicz SB (1993). Characterization of chromosome 9 deletions in transitional cell carcinoma by microsatellite assay. Hum Mol Genet 2:1407-1411.
21. Lunec J, Challen C, Wright C, Mellon K, and Neal DE (1992). C-erbB-2 amplification and identical p53 mutations in cocomitant transitional carcinomas of renal pelvis and urinary bladder. Lancet 339:439-440.
22. Mao L, Schoenberg MP, Scicchitano M, Erozan YS, Merlo A, Schwab D, and Sidransky D (1996). Molecular detection of primary bladder cancer by microsatellite analysis. Science 271:659-662.
23. Messing EM, and Catalona W (1997). Urothelial tumors of the urinary tract. In: Campbell's Urology, ed. 5, vol. 3:2327-2410. New York: Saunders.
24. Miyao N, Tsai YC, Lerner SP, Olumi AF, Spruck CH, 3d, Gonzalez Zulueta M, Nichols PW, Skinner DG, and Jones PA (1993). Role of chromosome 9 in human bladder cancer. Cancer Res 53:4066-4070.
25. Murphy WM, Beckwith JB, and Farrow GE (1994). Atlas of tumor pathology. In: Rosai J and Sobin LH, editors.Third Series, Fascicle 11, Tumors of the kidney, bladder, and related urinary structures. Washington, DC: Armed Forces Institute of Pathology.
26. Petersen I, Ohgaki H, Ludeke BI, and Kleihues P (1993). P53 mutations in phenacetin-associated human urothelial carcinomas. Carcinogenesis 14:2119-2122.
27. Rinaldi F, Mairs R, Wheldon T, Smith G, Yates A, and Symonds P (1995). Clonal analysis of phenacetin-implicated urothelial carcinoma. Int J Cancer 63:881-882.
28. Ruppert JM, Tokino K, and Sidransky D (1993). Evidence for two bladder cancer suppressor loci on human chromosome 9. Cancer Res 53:5093-5095.
29. Sauter G, Moch H, Carroll PC, Kerschmann R, Mihatsch MJ, and Waldman FM (1995). Chromosome-9 loss detected by fluorescence in situ hybridization in bladder cancer. Int J Cancer 64:99-103.
30. Schlegel J, Bocker T, Zirngibl H, Hofstädter F, and Rüschoff J (1995). Detection of microsatellite instability in human colorectal carcinomas using a non-radioactive PCR-based screening method. Virchows Arch 426:223-227.
31. Schütze K, and Lahr G (1998). Identification of expressed genes by laser-mediated manipulation of single cells. Nature Biotechnol 16:737-742.
32. Shepherd NS, Pfrogner BD, Coulby JN, Ackerman SL, Vaidyanathan G, Sauer RH, Balkenhol TC, and Sternberg N (1994). Preparation and screening of an arrayed human genomic library generated with the P1 cloning system. Proc Natl Acad Sci U S A 91:2629-2633.
33. Shigyo M, Sugano K, Fukayama N, Taniguchi T, Tobisu K, Fujimoto H, Doi N, Niwakawa M, Shimamura K, Tsukamoto T, Sekiya T, and Kakizoe T (1998). Allelic loss on chromosome 9 in bladder cancer tissues and urine samples detected by blunt-end single-strand DNA conformation polymorphism, Int J Cancer 78:425-429.
34. Sidransky D, Frost P, Von Eschenbach A, Oyashy R, Preisinger AC, and Vogelstein B (1992). Clonal origin of bladder cancer. N Engl J Med 326:737-740.
35. Simoneau AR, Spruck III CH, Gonzalez-Zulueta M, Gonzalgo ML, Chan MF, Tsai YS, Dean M, Steven K, Horn T, and Jones PA (1996). Evidence for two tumor suppressor loci associated with proximal chromosome 9p to q and distal chromosome 9q in bladder cancer and the initial screening for GAS1 and PTC mutations. Cancer Res 56:5039-5043.
36. Simoneau M, Aboulkassim TO, LaRue H, Rousseau F, and Fradet Y (1999). Four tumor suppressor loci on chromosome 9q in bladder cancer: evidence for two novel candidate regions at 9q22.3 and 9q31. Oncogene 18:157-163.
37. th ed. New York, Weinheim: Wiley-Liss.
38. Soloway MS, Jordan AM, and Murphy WM (1989). Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma. 310:215-236.
39. Spruck III CH, Ohneseit PF, Gonzalez-Zulueta M, Esrig D, Miyao N, Tsai YC, Lerner SP, Schmütte C, Yang AS, Core R, Dubeau L, Nichols PW, Hermann GG, Steven K, Horn T, Skinner DG, and Jones PA (1994). Two molecular pathways to transitional cell carcinomas of the bladder. Cancer Res 54:784-788.
40. Steiner G, Schoenberg MP, Linn JF, Mao L, and Sidransky D (1997). Detection of bladder cancer recurrence by microsatellite analysis of urine. Nat Med 3:621-624.
41. Takahashi T, Habuchi T, Kakehi Y, Mitsumori K, Akao T, Terachi T, and Yoshida O (1998). Clonal and chronological genetic analysis of multifocal cancers of the bladder and upper urinary tract. Cancer Res 58:5835-5841.
42. Tsai YC, Simoneau AR, Spruck III CH, Nichols PW, Steven K, Buckley JD, and Jones PA (1995). Mosaicism in human epithelium: Macroscopic monoclonal patches cover the urothelium. J Urol 153:1693-1700.
43. Xu X, Stower MJ, Reid N, Garner RC, and Burns PA (1996). Molecular screening of multifocal transitional cell carcinoma of the bladder using p53 mutations as biomarkers. Clin Cancer Res 2:1795-1800.